CARLOS VELAS: Open Payments
NPI 1447390455 · BETHLEHEM, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,236 in 202 payments from 11 companies in 2025. Trend: 2023 $1,852 · 2024 $2,404 · 2025 $3,236
Food & beverage: $3,126Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 50 | $642 |
| Neurocrine BioSciences, Inc. | 31 | $564 |
| Janssen Pharmaceuticals, Inc | 22 | $345 |
| E.R. Squibb & Sons, L.L.C. | 14 | $338 |
| Alkermes, Inc. | 16 | $333 |
| Otsuka America Pharmaceutical, Inc. | 13 | $237 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $217 |
| ABBVIE INC. | 21 | $212 |
| Vanda Pharmaceuticals Inc. | 8 | $139 |
| Lundbeck LLC | 15 | $135 |
Products named: INGREZZA, UZEDY, COBENFY, ARISTADA, REXULTI, INVEGA SUSTENNA, CAPLYTA, VRAYLAR.
Industry payments across PA — which companies pay providers there.
